 Eligible patients will undergo tissue biopsies to confirm diagnosis, followed by 3 to 4 cycles of neoadjuvant chemotherapy NACT. NACT will be paclitaxel and carboplatin in combination with pembrolizumab. A cycle will consist of pembrolizumab at 200mg IV, paclitaxel 175mgm2 IV, and carboplatin area under the curve AUC 5 or 6, on day 1 every 21 days. The length of each cycle is 21 days. This regimen will be followed by interval debulking surgery IDS. Adjuvant chemotherapy ACT will consist of 3 to 4 more cycles of paclitaxel with carboplatin plus pembrolizumab, once every 21 days. At the discretion of the treating physician dose-dense paclitaxel may be administered in the adjuvant setting weekly instead of once q3 weeks plus carboplatin once q21 days. 